Presentation TCT 2024 TCT 485: Device-Related Adverse Events and Modes of Failure Related to Renal Denervation Systems: Insights From Analysis of the FDA MAUDE Database Presenter: Manasa Jasti October 28, 2024
Presentation TCT 2024 TCT 486: Ultrasound Based Renal Denervation Reduces Blood Pressure in Patients With Chronic Kidney Disease: Results of a Multicenter Prospective Randomized Sham-Controlled Blinded Investigator Initiated Trial Presenter: Roland Schmieder October 28, 2024
Presentation TCT 2024 TCT 484: Twelve Week Safety and Efficacy of a Novel Extravascular Bi-lateral Renal Denervation Device in a Porcine Model at Nominal Dose Presenter: Abraham Tzafriri October 28, 2024
Presentation TCT 2024 TCT 482: Anatomical Predictors for Blood Pressure Outcome After Endovascular Ultrasound Renal Denervation Presenter: Karl Fengler October 28, 2024
Presentation TCT 2024 TCT 483: One Year Follow-Up Effect of Renal Sympathetic Denervation After Percutaneous Coronary Intervention in Patients With Resistant Hypertension and Type 2 Diabetes Mellitus Presenter: Daria Feshchenko October 28, 2024
Presentation TCT 2024 TCT 481: Renal Artery Imaging Through Long-Term Follow-Up Following Radiofrequency Renal Denervation: Results From the SPYRAL Clinical Trial Program Presenter: Felix Mahfoud October 28, 2024
Presentation TCT 2024 TCT 480: Blood Pressure Reductions by Radiofrequency Renal Denervation Procedural Characteristics: Pooled 24-Month Results From the SYMPLICITY Clinical Program Presenter: Felix Mahfoud October 28, 2024
Presentation TCT 2024 Digital Era in Dermatology with Noninvasive Virtual Skin Biopsies (Enspectra Health) (69301) Presenter: Gabriel Sanchez October 27, 2024
Presentation TCT 2024 Too Good to Be True? Five Top Lessons of Major GLP-1 Agonists Trials Presenter: C. Michael Gibson October 27, 2024
Presentation TCT 2024 How Great if True: My Futuristic View in How GLP-1 Agonist Will Continue Expanding Its Therapeutic Reach Presenter: Marc Bonaca October 27, 2024
Presentation ESC 2024 BedMed and BedMed-Frail randomized controlled trials Presenter: Scott Garrison August 31, 2024
Presentation ESC 2024 QUADRO Phase III Study: Efficacy and Safety of the new Quadruple SPC Perindopril/Indapamide/Amlodipine/Bisoprolol in Patients with Resistant Hypertension Presenter: Stefano Taddei August 31, 2024
Presentation ESC 2024 Continuation versus Interruption of Oral Anticoagulation during TAVI Presenter: Dirk-Jan van Ginkel August 31, 2024
Presentation NY Valves 2024 Real World TTVI Registries: Is There Concordance With the Randomized Trials? Presenter: Bassem M. Chehab June 07, 2024
Presentation NY Valves 2024 Transcatheter Tricuspid Valve Replacement - TRISCEND II Presenter: Raj Makkar June 07, 2024
Presentation EuroPCR 2024 Impact of valve type and anaesthesia strategy for TAVI – 5-year results of the SOLVE-TAVI trial Presenter: Hans-Josef Feistritzer May 14, 2024
Presentation ACC 2024 Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC) Presenter: Rasha K. Al-Lamee April 08, 2024
Presentation ACC 2024 Evaluation of a Technology Assisted Web Application to Qualify for Nonprescription Statin Administration Presenter: Steven E. Nissen April 08, 2024
Presentation ACC 2024 Effect of Alcohol-mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 3-month Primary Results From the Target BP I Randomized Trial Presenter: David E. Kandzari April 08, 2024